UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

23 UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Read More Share:

Apr

16 UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

Read More Share:

Feb

25 UCB - Sustaining Growth, Now and Into the Future

Read More Share:

Feb

23 UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Read More Share:

Feb

05 The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Read More Share:

Jan

12 UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

Read More Share:

Nov

30 World's Leading Life Science Companies Now Enrolling COMMUNITY, a Global, Platform Trial for Hospitalized Patients with COVID-19

Read More Share:

Nov

17 UCB’s VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

Read More Share:

Nov

12 UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Read More Share:

Nov

05 UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

Read More Share:

Categories

Archives

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Apr

16

UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Feb

23

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Feb

05

The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Jan

12

UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

Nov

30

World's Leading Life Science Companies Now Enrolling COMMUNITY, a Global, Platform Trial for Hospitalized Patients with COVID-19

Nov

17

UCB’s VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

Nov

12

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Nov

05

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Apr

16

UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Feb

23

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Feb

05

The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Jan

12

UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

Nov

30

World's Leading Life Science Companies Now Enrolling COMMUNITY, a Global, Platform Trial for Hospitalized Patients with COVID-19

Nov

17

UCB’s VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

Nov

12

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Nov

05

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact